What is the management of herpes zoster (shingles) on the face?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Management of Facial Shingles (Herpes Zoster)

For facial herpes zoster, initiate oral valacyclovir 1 gram three times daily for 7 days as soon as possible, ideally within 72 hours of rash onset, and continue treatment until all lesions have scabbed. 1, 2, 3

Antiviral Treatment Algorithm

First-Line Oral Therapy (Uncomplicated Cases)

  • Valacyclovir 1 gram orally three times daily for 7 days is the preferred first-line treatment 1, 2, 3
  • Alternative option: Acyclovir 800 mg orally five times daily for 7 days 1, 2
  • Alternative option: Famciclovir 500 mg every 8 hours for 7 days 2, 4
  • Treatment should be initiated within 72 hours of rash onset for optimal efficacy, though benefit may still occur with later initiation 1, 5
  • Continue treatment until all lesions have scabbed, which may require extending beyond 7 days in some cases 1, 2

Intravenous Therapy (Severe/Complicated Cases)

  • Intravenous acyclovir 5-10 mg/kg every 8 hours is indicated for: 6, 1, 2
    • Disseminated herpes zoster
    • Multi-dermatomal involvement
    • Ophthalmic zoster with severe complications
    • Immunocompromised patients with severe disease
    • Visceral involvement
  • Switch to oral therapy once clinical improvement occurs 2
  • Continue IV treatment until clinical resolution is attained 2

Special Considerations for Facial Involvement

Ophthalmic Zoster

  • Facial zoster requires particular attention due to risk of cranial nerve complications 1
  • Ophthalmic involvement generally merits referral to an ophthalmologist 7
  • Use the same antiviral regimens as for other facial zoster 5

Supportive Care Measures

  • Elevate the affected area to promote drainage of edema and inflammatory substances 1
  • Keep skin well hydrated with emollients to avoid dryness and cracking 1
  • Consider topical analgesics for symptomatic relief, though these do not replace systemic antiviral therapy 6

Management in Immunocompromised Patients

  • All immunocompromised patients require antiviral treatment regardless of timing 2
  • Consider temporary reduction in immunosuppressive medications for disseminated or invasive disease 1, 2
  • Immunosuppression may be restarted after commencing antiviral therapy and resolution of skin vesicles 2
  • Monitor closely for dissemination and visceral complications 2
  • Laboratory confirmation may be needed if clinical presentation is atypical 1

Dosing Adjustments for Renal Impairment

  • Reduce valacyclovir dose based on creatinine clearance: 3
    • CrCl 30-49 mL/min: 1 gram every 12 hours
    • CrCl 10-29 mL/min: 1 gram every 24 hours
    • CrCl <10 mL/min: 500 mg every 24 hours
  • Similar dose adjustments apply to acyclovir and famciclovir 2, 4

Pain Management

  • Acute pain control may require narcotics for adequate relief 7
  • Tricyclic antidepressants or anticonvulsants in low doses can help control neuropathic pain 7
  • Adjunctive corticosteroids (prednisone) may provide modest benefits in reducing acute pain in select cases of severe, widespread disease, but should be avoided in immunocompromised patients 1
  • Capsaicin cream and lidocaine patches can be used for localized pain relief 7

Critical Pitfalls to Avoid

  • Do not use topical antiviral therapy alone - it is substantially less effective than systemic therapy and is not recommended 1
  • Do not delay treatment waiting for laboratory confirmation in typical presentations - initiate antivirals based on clinical diagnosis 1
  • Do not stop treatment at 7 days if new lesions continue to form or healing is incomplete 2
  • Do not use corticosteroids in immunocompromised patients due to increased risk of disseminated infection 1

Acyclovir-Resistant Cases

  • For suspected acyclovir-resistant herpes zoster, foscarnet 40 mg/kg IV every 8 hours is recommended 2
  • Acyclovir-resistant isolates are routinely resistant to ganciclovir as well 2

Prevention

  • Recombinant zoster vaccine (Shingrix) is recommended for adults aged 50 years and older regardless of prior herpes zoster episodes 1
  • Vaccination should ideally occur before initiating immunosuppressive therapies 1

References

Guideline

Management of Herpes Zoster

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Treatment of Herpes Zoster

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.